Disc Medicine (IRON) in Pivotal Point Check: FDA Submission Following Phase 3 Data on Bitopertin and 350 Million USD Placement Secures Market Entry 2027!
Reading Time: 2 minutes
Study Success as a Price Driver: Achieving all primary and secondary endpoints in the pivotal Phase 3 study APOLLO for Bitopertin triggered a massive jump in the stock price. Clear Roadmap to Commercialization: The reduction of harmful PPIX levels by 41.4% and the extension of pain-free light exposure create the basis for the FDA submission. Strategic Capital Measure for Market Launch: An announced capital increase of 350 million USD secures the financial resources needed for the sales launch preparations starting mid-2027. Disc Medicine...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
